Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07281261

tAN for Substance Use Disorder

Study of Transcutaneous Auricular Neurostimulation as a Treatment for Substance Use Disorder

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Spark Biomedical, Inc. · Industry
Sex
All
Age
18 Years – 64 Years
Healthy volunteers
Not accepted

Summary

The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD). Enrolled participants will wear the tAN device on-site (at The Menninger Clinic) for the 5-day detox treatment period. Participants with AUD will be single-blinded randomized into 2 groups - a treatment group (active tAN) and a placebo group (sham tAN). Each group will consist of five separate time points - admission, screening, baseline, tAN treatment, and post tAN treatment. Clinical measures collected before, during, and after treatment will include alcohol withdrawal severity, craving, benzodiazepine usage, and assessments of depression and suicidal behaviors. Participants will undergo MRI scans before and after the treatment period to assess changes in brain connectivity and their relationship to clinical outcomes.

Conditions

Interventions

TypeNameDescription
DEVICESparrow AscentThe Sparrow Ascent is an FDA-cleared (K230796) wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and around the auricle. The system is comprised of a Patient Controller, cable, and 24-hour disposable earpiece.
DEVICESparrow Ascent (Sham)Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. The sham device has an identical appearance to the active device.

Timeline

Start date
2026-01-28
Primary completion
2026-08-31
Completion
2026-08-31
First posted
2025-12-15
Last updated
2026-04-08

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07281261. Inclusion in this directory is not an endorsement.